Exact Mass: 674.246

Exact Mass Matches: 674.246

Found 86 metabolites which its exact mass value is equals to given mass value 674.246, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

(N-acetylneuraminosyl(a2-6)lactosamine)

(2R,4S,5R,6R)-5-Acetamido-2-{[(2R,3R,4S,5R,6S)-6-{[(2R,3S,4R,5R,6R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

C25H42N2O19 (674.2382)


(N-acetylneuraminosyl(alpha2-6)lactosamine) is widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,6-linked to N-acetylgalactosamine (GalNAc). The biosynthesis of the linkage is mediated by a member of the sialyltransferase family, the beta-galactoside alpha,6-sialyltransferase (EC 2.4.99.1, ST6Gal.I). Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. (PMID 11425186)

.

6-Sialyllactosamine is an oligosaccharide found in human milk. Oligosaccharides in human milk inhibit enteric pathogens in vitro and in vivo. (PMID:10683228)

.

(N-acetylneuraminosyl(alpha2-6)lactosamine) is widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,6-linked to N-acetylgalactosamine (GalNAc). The biosynthesis of the linkage is mediated by a member of the sialyltransferase family, the beta-galactoside alpha,6-sialyltransferase (EC 2.4.99.1, ST6Gal.I). Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. (PMID 11425186)

   

3-Sialyl-N-acetyllactosamine

(2R,4S,5R,6R)-2-{[(2S,3R,4S,5S,6R)-2-{[(2R,3S,4R,5R)-4,5-dihydroxy-6-[(1-hydroxyethylidene)amino]-2-(hydroxymethyl)oxan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-5-[(1-hydroxyethylidene)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate

C25H42N2O19 (674.2382)


3-Sialyl-N-acetyllactosamine is a normal sialyloligosaccharide that is present in human biofluids, and is one of the predominant oligosaccharides in human urine as a free form. The presence of these compounds in the urine is linked to the biosynthesis and degradation of the body glycoproteins, glycolipids, and glycans. Under certain pathological conditions, the total urinary carbohydrate-material is increased dramatically, and the number and ratios of the components present are also increased. Many of these pathological disorders are the result of a deficiency in a specific exoglycosidase. 3-Sialyl-N-acetyllactosamine have a sialyl(a2-3) linkage and is of interest in view of the discovery of uropathogenic Escherichia coli strains with binding specificity for sialyl(a2-3)galactosides. (PMID: 2445744; 2775488; 3813552; 6619126; 6628386; 6628680; 6714239; 6746638; 7925342) [HMDB] 3-Sialyl-N-acetyllactosamine is a normal sialyloligosaccharide that is present in human biofluids, and is one of the predominant oligosaccharides in human urine as a free form. The presence of these compounds in the urine is linked to the biosynthesis and degradation of the body glycoproteins, glycolipids, and glycans. Under certain pathological conditions, the total urinary carbohydrate-material is increased dramatically, and the number and ratios of the components present are also increased. Many of these pathological disorders are the result of a deficiency in a specific exoglycosidase. 3-Sialyl-N-acetyllactosamine have a sialyl(a2-3) linkage and is of interest in view of the discovery of uropathogenic Escherichia coli strains with binding specificity for sialyl(a2-3)galactosides. (PMID: 2445744; 2775488; 3813552; 6619126; 6628386; 6628680; 6714239; 6746638; 7925342).

   

6-Sialyl-N-acetyllactosamine

(2S,4S,5R,6R)-2-{[(2R,3R,4S,5R,6S)-6-{[(2R,3S,4R,5R)-4,6-dihydroxy-5-[(1-hydroxyethylidene)amino]-2-(hydroxymethyl)oxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}-4-hydroxy-5-[(1-hydroxyethylidene)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate

C25H42N2O19 (674.2382)


6-Sialyl-N-acetyllactosamine is an oligosaccharide widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,3- or alpha,6-linked to galactose (Gal), alpha,6-linked to N-acetylgalactosamine (GalNAc) or alpha,8-linked to another sialic acid. The biosynthesis of the various linkages is mediated by the different members of the sialyltransferase family. The b-galactoside a2,6 sialyltransferase (EC 2.4.99.1, ST6Gal.I) is the only sialyltransferase so far identified able to catalyze the a2,6-sialylation of lactosamine. Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. The level of expression of the sialyl-alpha2,6-lactosaminyl structures and of ST6Gal.I show a strong dependence on neoplastic transformation and differentiation in several tissues. (PMID: 11425186) [HMDB] 6-Sialyl-N-acetyllactosamine is an oligosaccharide widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,3- or alpha,6-linked to galactose (Gal), alpha,6-linked to N-acetylgalactosamine (GalNAc) or alpha,8-linked to another sialic acid. The biosynthesis of the various linkages is mediated by the different members of the sialyltransferase family. The b-galactoside a2,6 sialyltransferase (EC 2.4.99.1, ST6Gal.I) is the only sialyltransferase so far identified able to catalyze the a2,6-sialylation of lactosamine. Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. The level of expression of the sialyl-alpha2,6-lactosaminyl structures and of ST6Gal.I show a strong dependence on neoplastic transformation and differentiation in several tissues. (PMID: 11425186).

   

3'-Sialyl-N-acetyllactosamine

2-{[2-({4,6-dihydroxy-5-[(1-hydroxyethylidene)amino]-2-(hydroxymethyl)oxan-3-yl}oxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-5-[(1-hydroxyethylidene)amino]-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylate

C25H42N2O19 (674.2382)


   

Dirlotapide

N-{2-[Benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-{[4-(trifluoromethyl)[1,1-biphenyl]-2-carbonyl]amino}-1H-indole-2-carboxamide

C40H33F3N4O3 (674.2505)


   

3-b-Sialyl-N-acetyllactosamine

3-b-Sialyl-N-acetyllactosamine

C25H42N2O19 (674.2382)


   

Halistanol sulfate G

(2beta,3alpha,5alpha,6alpha)-ergostane-2,3,6-triyl tris(hydrogen sulfate)

C28H50O12S3 (674.2464)


   
   
   

rehmaglutosides C

rehmaglutosides C

C30H42O17 (674.2422)


   

3-SLN

5-acetamido-2-[2-(5-acetamido-1,2,4-trihydroxy-6-oxohexan-3-yl)oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid

C25H42N2O19 (674.2382)


   

NeuAc alpha,6gal beta1,4gicnac

O-(N-Acetyl-alpha-neuraminosyl)-(2->6)-O-beta-D-galactopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-D-glucose

C25H42N2O19 (674.2382)


   

IR-746 DYE CONTENT 85

IR-746 DYE CONTENT 85

C35H43N2NaO6S2 (674.246)


   

O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-D-galactose

O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-D-galactose

C25H42N2O19 (674.2382)


   

Dirlotapide

Dirlotapide

C40H33F3N4O3 (674.2505)


C78272 - Agent Affecting Nervous System > C29728 - Anorexiant

   
   

Neu5Acalpha2-3Galbeta1-3GlcNAcbeta

Neu5Acalpha2-3Galbeta1-3GlcNAcbeta

C25H42N2O19 (674.2382)


   

1-[(2R,3R)-2-[[2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(1-naphthalenyl)urea

1-[(2R,3R)-2-[[2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(1-naphthalenyl)urea

C35H38N4O8S (674.241)


   

NeuAc(a2-6)Gal(b1-4)GlcNAc

NeuAc(a2-6)Gal(b1-4)GlcNAc

C25H42N2O19 (674.2382)


   

beta-D-galactosyl-(1->3)-[alpha-N-acetylneuraminosyl-(2->6)]-N-acetyl-alpha-D-galactosamine

beta-D-galactosyl-(1->3)-[alpha-N-acetylneuraminosyl-(2->6)]-N-acetyl-alpha-D-galactosamine

C25H42N2O19 (674.2382)


   

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc

C25H42N2O19 (674.2382)


   

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc

C25H42N2O19 (674.2382)


   

3-alpha-Sialyl-N-acetyllactosamine

3-alpha-Sialyl-N-acetyllactosamine

C25H42N2O19 (674.2382)


   

beta-NeupNAc-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc

beta-NeupNAc-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc

C25H42N2O19 (674.2382)


   

Gal(b1-3)[NeuAc(a2-6)]a-GlcNAc

Gal(b1-3)[NeuAc(a2-6)]a-GlcNAc

C25H42N2O19 (674.2382)


   

2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-beta-D-galactopyranose

2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-beta-D-galactopyranose

C25H42N2O19 (674.2382)


   

Gal(b1-3)[NeuAc(a2-6)]b-GlcNAc

Gal(b1-3)[NeuAc(a2-6)]b-GlcNAc

C25H42N2O19 (674.2382)


   

Gal(b1-3)[NeuAc(a2-6)]b-GalNAc

Gal(b1-3)[NeuAc(a2-6)]b-GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Man(b1-4)GlcNAc

NeuAc(a2-6)Man(b1-4)GlcNAc

C25H42N2O19 (674.2382)


   

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-D-GalpNAc

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-D-GalpNAc

C25H42N2O19 (674.2382)


   

Gal(b1-3)[NeuAc(a2-6)]GalNAc

Gal(b1-3)[NeuAc(a2-6)]GalNAc

C25H42N2O19 (674.2382)


   

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc

C25H42N2O19 (674.2382)


   

beta-D-Galp-(1->3)-[beta-Neup5Ac-(2->6)]-alpha-D-GalpNAc

beta-D-Galp-(1->3)-[beta-Neup5Ac-(2->6)]-alpha-D-GalpNAc

C25H42N2O19 (674.2382)


   

Gal(a1-3)[NeuAc(a2-6)]a-GalNAc

Gal(a1-3)[NeuAc(a2-6)]a-GalNAc

C25H42N2O19 (674.2382)


   

2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-D-galactopyranose

2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-D-galactopyranose

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-4)a-GlcNAc

NeuAc(a2-6)Gal(b1-4)a-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-3)a-GalNAc

NeuAc(a2-6)Gal(b1-3)a-GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)Gal(b1-4)a-GlcNAc

NeuAc(a2-3)Gal(b1-4)a-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-3)GalNAc

NeuAc(a2-6)Gal(b1-3)GalNAc

C25H42N2O19 (674.2382)


   

Gal(a1-3)[NeuAc(a2-6)]GalNAc

Gal(a1-3)[NeuAc(a2-6)]GalNAc

C25H42N2O19 (674.2382)


   

3-a-Sialyl-N-acetyllactosamine

3-a-Sialyl-N-acetyllactosamine

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(a1-3)a-GalNAc

NeuAc(a2-6)Gal(a1-3)a-GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-3)b-GalNAc

NeuAc(a2-6)Gal(b1-3)b-GalNAc

C25H42N2O19 (674.2382)


   

Gal(b1-4)[NeuAc(a2-6)]GalNAc

Gal(b1-4)[NeuAc(a2-6)]GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-3)GlcNAc

NeuAc(a2-6)Gal(b1-3)GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(b2-3)Gal(b1-3)a-GalNAc

NeuAc(b2-3)Gal(b1-3)a-GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(b2-6)GalNAc(b1-4)Glc

NeuAc(b2-6)GalNAc(b1-4)Glc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)GalNAc(b1-4)Glc

NeuAc(a2-6)GalNAc(b1-4)Glc

C25H42N2O19 (674.2382)


   

Gal(b1-3)[NeuAc(a2-6)]GlcNAc

Gal(b1-3)[NeuAc(a2-6)]GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-4)HexNAc

NeuAc(a2-6)Gal(b1-4)HexNAc

C25H42N2O19 (674.2382)


   

5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2->3)-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose

5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2->3)-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose

C25H42N2O19 (674.2382)


   

D-galacto-hexopyranosyl-(1->3)-[5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->6)]-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose

D-galacto-hexopyranosyl-(1->3)-[5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->6)]-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose

C25H42N2O19 (674.2382)


   

Neu5Acalpha2-6GlcNAcbeta1-3Galbeta

Neu5Acalpha2-6GlcNAcbeta1-3Galbeta

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)Gal(a1-3)b-GlcNAc

NeuAc(a2-3)Gal(a1-3)b-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)Gal(a1-4)b-GlcNAc

NeuAc(a2-3)Gal(a1-4)b-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Glc(b1-4)b-GlcNAc

NeuAc(a2-6)Glc(b1-4)b-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Glc(b1-4)GlcNAc

NeuAc(a2-6)Glc(b1-4)GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(b1-3)b-GlcNAc

NeuAc(a2-6)Gal(b1-3)b-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(b2-6)Gal(b1-4)a-GlcNAc

NeuAc(b2-6)Gal(b1-4)a-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)GalNAc(b1-3)Gal

NeuAc(a2-3)GalNAc(b1-3)Gal

C25H42N2O19 (674.2382)


   

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-D-galacto-hexopyranose

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-D-galacto-hexopyranose

C25H42N2O19 (674.2382)


   

3-O-[3-O-[(N-Acetyl-2-deoxy-alpha-neuraminic acid)-2-yl]-D-galactopyranosyl]-2-(acetylamino)-2-deoxy-D-galactopyranose

3-O-[3-O-[(N-Acetyl-2-deoxy-alpha-neuraminic acid)-2-yl]-D-galactopyranosyl]-2-(acetylamino)-2-deoxy-D-galactopyranose

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)Gal(b1-4)GalNAc

NeuAc(a2-3)Gal(b1-4)GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Gal(a1-3)GalNAc

NeuAc(a2-6)Gal(a1-3)GalNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-6)Man(b1-4)b-GlcNAc

NeuAc(a2-6)Man(b1-4)b-GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(b2-3)Gal(b1-3)GalNAc

NeuAc(b2-3)Gal(b1-3)GalNAc

C25H42N2O19 (674.2382)


   

D-galacto-hexopyranosyl-(1->3)-[5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->6)]-2-acetamido-2-deoxy-D-galacto-hexopyranose

D-galacto-hexopyranosyl-(1->3)-[5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->6)]-2-acetamido-2-deoxy-D-galacto-hexopyranose

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)Gal(b1-3)GlcNAc

NeuAc(a2-3)Gal(b1-3)GlcNAc

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)GalNAc(b1-4)Glc

NeuAc(a2-3)GalNAc(b1-4)Glc

C25H42N2O19 (674.2382)


   

NeuAc(a2-3)Gal(b1-3)a-GlcNAc

NeuAc(a2-3)Gal(b1-3)a-GlcNAc

C25H42N2O19 (674.2382)


   

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose

C25H42N2O19 (674.2382)


   

Gal(b1-3)[NeuAc(b2-6)]b-GalNAc

Gal(b1-3)[NeuAc(b2-6)]b-GalNAc

C25H42N2O19 (674.2382)


   

5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2->3)-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-hexopyranose

5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2->3)-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-hexopyranose

C25H42N2O19 (674.2382)


   

Neu5Acalpha2-6GlcNAcbeta1-3Glcbeta

Neu5Acalpha2-6GlcNAcbeta1-3Glcbeta

C25H42N2O19 (674.2382)


   

6-Sialyllactosamine

6-Sialyllactosamine

C25H42N2O19 (674.2382)


   

3-Sialyl-N-acetyllactosamine

3-Sialyl-N-acetyllactosamine

C25H42N2O19 (674.2382)


   

6-Sialyl-N-acetyllactosamine

6-Sialyl-N-acetyllactosamine

C25H42N2O19 (674.2382)


   

(2beta,3alpha,5alpha,6alpha)-ergostane-2,3,6-triyl tris(hydrogen sulfate)

(2beta,3alpha,5alpha,6alpha)-ergostane-2,3,6-triyl tris(hydrogen sulfate)

C28H50O12S3 (674.2464)


   

Halistanol sulfonic acid G

Halistanol sulfonic acid G

C28H50O12S3 (674.2464)


A steroid sulfate that is 5alpha-ergostane substituted by sulfate groups at positions 2, 3 and 6 (the (2beta,3alpha,6alpha stereoisomer).

   
   

(2s,4s,5r,6r)-6-[(1r,2r)-2,3-dihydroxy-1-{[(2s,3r,4r,5s,6r)-5-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}propyl]-2,4-dihydroxy-5-[(1-hydroxyethylidene)amino]oxane-2-carboxylic acid

(2s,4s,5r,6r)-6-[(1r,2r)-2,3-dihydroxy-1-{[(2s,3r,4r,5s,6r)-5-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}propyl]-2,4-dihydroxy-5-[(1-hydroxyethylidene)amino]oxane-2-carboxylic acid

C25H42N2O19 (674.2382)


   

6-[2,3-dihydroxy-1-({5-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl}oxy)propyl]-2,4-dihydroxy-5-[(1-hydroxyethylidene)amino]oxane-2-carboxylic acid

6-[2,3-dihydroxy-1-({5-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl}oxy)propyl]-2,4-dihydroxy-5-[(1-hydroxyethylidene)amino]oxane-2-carboxylic acid

C25H42N2O19 (674.2382)


   

[6-({19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl}oxy)-3,4,5-trihydroxyoxan-2-yl]methyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

[6-({19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl}oxy)-3,4,5-trihydroxyoxan-2-yl]methyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C36H38N2O11 (674.2475)


   

(1s,4ar,5r,7s,7as)-7-hydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-5-yl 3,5-dimethoxy-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}benzoate

(1s,4ar,5r,7s,7as)-7-hydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-5-yl 3,5-dimethoxy-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}benzoate

C30H42O17 (674.2422)


   

[(2r,3s,4s,5r,6s)-6-{[(1r,18s,19r,20s)-19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

[(2r,3s,4s,5r,6s)-6-{[(1r,18s,19r,20s)-19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C36H38N2O11 (674.2475)